Royal London Asset Management
JAZZ icon

Royal London Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Royal London Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,978
Closed -$2.56M – 652
2024
Q2 		$2.56M Buy
23,978
+1,215
+5% +$134K 0.01% 606
2024
Q1 		$2.74M Sell
22,763
-471
-2% -$57.7K 0.01% 610
2023
Q4 		$2.86M Sell
23,234
-40
-0.2% -$4.99K 0.01% 606
2023
Q3 		$3.01M Buy
23,274
+2,049
+10% +$273K 0.01% 599
2023
Q2 		$2.63M Buy
21,225
+1,807
+9% +$243K 0.01% 601
2023
Q1 		$2.84M Buy
19,418
+2,033
+12% +$301K 0.01% 576
2022
Q4 		$2.77M Sell
17,385
-402
-2% -$58.9K 0.01% 578
2022
Q3 		$2.37M Sell
17,787
-3,448
-16% -$524K 0.01% 577
2022
Q2 		$3.31M Buy
21,235
+116
+0.5% +$17.9K 0.02% 544
2022
Q1 		$3.29M Buy
21,119
+884
+4% +$128K 0.01% 584
2021
Q4 		$2.58M Buy
20,235
+2,099
+12% +$276K 0.01% 598
2021
Q3 		$2.36M Buy
18,136
+783
+5% +$118K 0.01% 612
2021
Q2 		$3.08M Hold
17,353
– – 0.01% 604
2021
Q1 		$2.85M Hold
17,353
– – 0.01% 599
2020
Q4 		$2.87M Sell
17,353
-4,345
-20% -$647K 0.02% 551
2020
Q3 		$3.03M Hold
21,698
– – 0.02% 505
2020
Q2 		$2.38M Sell
21,698
-3,133
-13% -$346K 0.02% 526
2020
Q1 		$2.48M Hold
24,831
– – 0.02% 505
2019
Q4 		$3.69M Hold
24,831
– – 0.03% 494
2019
Q3 		$3.18M Buy
+24,831
New +$3.33M 0.02% 517
2019
Q2 		– Sell
-22,667
Closed -$3.24M – 613
2019
Q1 		$3.24M Sell
22,667
-2,894
-11% -$377K 0.03% 526
2018
Q4 		$3.11M Sell
25,561
-31,011
-55% -$4.6M 0.03% 519
2018
Q3 		$5.49M Buy
56,572
+30,897
+120% +$5.31M 0.06% 323
2018
Q2 		$4.42M Buy
+25,675
New +$4.2M 0.04% 416

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal London Asset Management's JAZZ Position: Q3 2024 in Review

Royal London Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 23,978 shares — an estimated $2.56M sold.

Royal London Asset Management first reported a position in JAZZ in Q2 2018 and held it in 24 quarters. The position peaked at $5.49M in Q3 2018. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Royal London Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Royal London Asset Management sold 23,978 Jazz Pharmaceuticals shares in Q3 2024, an estimated $2.56M.
  • Royal London Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 24 quarters.
  • Royal London Asset Management's Jazz Pharmaceuticals position peaked at $5.49M in Q3 2018.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Royal London Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.